Namwiwat Medical PCL (BKK:NAM) Change In Receivables: ฿100 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:NAM Namwiwat Medical Corp PCL BKK:NAM
35 GF Score
Price ฿3.30
GF Value ฿5.87
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Namwiwat Medical PCL Change In Receivables?

Namwiwat Medical PCL BKK:NAM 35 Change In Receivables is ฿100 Mil as of Mar. 2026. GuruFocus rates BKK:NAM with a GF Score™ of 35/100 and a GF Value™ of ฿5.87 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Namwiwat Medical PCL's change in receivables for the quarter that ended in Mar. 2026 was ฿46 Mil. It means Namwiwat Medical PCL's Accounts Receivable declined by ฿46 Mil from Dec. 2025 to Mar. 2026 .

Namwiwat Medical PCL's change in receivables for the fiscal year that ended in Dec. 2025 was ฿242 Mil. It means Namwiwat Medical PCL's Accounts Receivable declined by ฿242 Mil from Dec. 2024 to Dec. 2025 .

Namwiwat Medical PCL's Accounts Receivable for the quarter that ended in Mar. 2026 was ฿533 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Namwiwat Medical PCL's Days Sales Outstanding for the three months ended in Mar. 2026 was 128.97.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Namwiwat Medical PCL's liquidation value for the three months ended in Mar. 2026 was ฿653 Mil.

Namwiwat Medical PCL  (BKK:NAM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Namwiwat Medical PCL's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=532.638/376.87*91
=128.97

2. In Ben Graham's calculation of liquidation value, Namwiwat Medical PCL's accounts receivable are only considered to be worth 75% of book value:

Namwiwat Medical PCL's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=678.116-780.245+0.75 * 532.638+0.5 * 710.473
=653

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Namwiwat Medical PCL Change In Receivables Related Terms

Namwiwat Medical PCL Change In Receivables Historical Data

* Premium members only.

The historical data trend for Namwiwat Medical PCL's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Namwiwat Medical PCL Change In Receivables Chart

Namwiwat Medical PCL Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial -10.00 -255.35 113.61 -262.16 241.50

Namwiwat Medical PCL Quarterly Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 187.08 41.01 -22.18 35.60 45.60
BKK:NAM
35GF Score
Namwiwat Medical Corp PCL BKK:NAM
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Namwiwat Medical PCL Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿100 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of ฿100 Mil mean?
Namwiwat Medical PCL (BKK:NAM) has a Change In Receivables of ฿100 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Namwiwat Medical PCL and its competitors.
Is Namwiwat Medical PCL's Change In Receivables too high?
Namwiwat Medical PCL's current Change In Receivables is ฿100 Mil. Overall, Namwiwat Medical PCL has a GF Score™ of 35/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's Change In Receivables compare to ABT and SYK?
Namwiwat Medical PCL's Change In Receivables of ฿100 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Namwiwat Medical PCL and its competitors. Namwiwat Medical PCL's current Change In Receivables is ฿100 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿5.87, compared to a current price of ฿3.30 — trading 43.8% below its estimated fair value. The current Change In Receivables is ฿100 Mil. Namwiwat Medical PCL's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current Change In Receivables is ฿100 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?

Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued. The current stock price of ฿3.30 is trading 43.8% below its estimated GF Value™ of ฿5.87. GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.

Key valuation signals for BKK:NAM:

  • Change In Receivables: ฿100 Mil
  • GF Value™: ฿5.87 vs. price of ฿3.30 (43.8% below fair value)
  • GF Score™: 35/100 with 3 warning signs

No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Namwiwat Medical PCL Business Description

Address 999/3-5 Moo 9 Prachauthit - Ku Sang Road, Nai Khlong Bang Pla Kot, Phra Samut Chedi, Samut Prakan, THA, 10290
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
35GF Score

Get the complete analysis for BKK:NAM

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿3.30
Price
฿5.87
GF Value